ProQR Therapeutics N.V.
PRQR
NASDAQ·Healthcare·Biotechnology·Mkt cap $218.0M
$2.07
▼ -0.96%
P/E
-4.49
Mkt Cap
$218.0M
52-Wk Range
$1.33–$3.10
52-Week Range
$1.33 - $3.10
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 11.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
Mild headwinds expected
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+35.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying PRQR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 13, 2026
Reported EPS of -$0.10 vs -$0.13 consensus (+23.2% surprise). Revenue of $10.0M vs $4.6M expected (+119.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+23.2%
Revenue trend · last 8Q
—
—
—
—
-24%
+9%
-55%
+133%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$4.5M
$5.0M
$5.3M
$4.5M
$3.4M
$5.5M
$2.4M
$10.4M
Margins · last 8Q
Profit
-99.7%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Bank of America · Aug 20, 2026
vs Industry
How PRQR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.